Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Public ClinicalTrials.gov record NCT02228304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2. Those who, in the opinion of the investigator, are still candidates for continued anti-VEGF therapy will be re-implanted with a new NT-503-3 investigational product and followed for an additional 12 weeks before study exit. Stage 2 (Phase II) is a separate, randomized, masked phase during which eligible patients will be randomized to the NT-503-3 group or the control group. Clinical Hypotheses: * NT-503-3 ECT is comparable to Eylea® injected intravitreally every 8 weeks in the prevention of vision loss due to recurrent CNV secondary to AMD * NT-503-3 ECT has an acceptable safety profile
Study identification
- NCT ID
- NCT02228304
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2014 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Apr 2016 (Actual)
- Last update posted
- Jul 18, 2022
2014 – 2016
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Associated Retina Consultants, Ltd. | Phoenix | Arizona | 85020 | — |
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| University of California, Irvine, The Gavin Herbert Eye Institute | Irvine | California | 92697 | — |
| Jacobs Retina Center at UCSD | La Jolla | California | 92093 | — |
| Colorado Retina Associates | Golden | Colorado | 80401 | — |
| Retina Health Center | Fort Myers | Florida | 33907 | — |
| National Ophthalmic Research Institute | Fort Myers | Florida | 33912 | — |
| Center for Retina and Macular Disease | Winter Haven | Florida | 33880 | — |
| Southeast Retina Center, PC | Augusta | Georgia | 30909 | — |
| Georgina Retina, P.C. | Marietta | Georgia | 30060 | — |
| Illinois Retina Associates, S.C. | Joliet | Illinois | 60435 | — |
| Illinois Retina Associates | Oak Park | Illinois | 60304 | — |
| Retina Associates of Kentucky | Lexington | Kentucky | 40509 | — |
| The Retina Group of Washington | Chevy Chase | Maryland | 20815 | — |
| Cumberland Valley Retina Consultants, PC | Hagerstown | Maryland | 21740 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| University of Michigan, Kellogg Eye Center | Ann Arbor | Michigan | 48105 | — |
| William Beaumont Hospital-Ophthalmology Research | Royal Oak | Michigan | 48073 | — |
| Lifelong Vision Foundation | Chesterfield | Missouri | 63017 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| Retina Center of New Jersey, LLC | Bloomfield | New Jersey | 07003 | — |
| NJ Retina | New Brunswick | New Jersey | 08901 | — |
| Western Carolina Retinal Associates | Asheville | North Carolina | 28803 | — |
| Wake Forest Baptist Health Eye Center | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Retina Northwest, PC | Portland | Oregon | 97210 | — |
| Mid Atlantic Retina | Philadelphia | Pennsylvania | 19107 | — |
| Palmetto Retina Center, LLC | Florence | South Carolina | 29501 | — |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | — |
| Valley Retina Institute, PA | McAllen | Texas | 78503 | — |
| Medical Center Ophthalmology Associates | San Antonio | Texas | 78240 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02228304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2022 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02228304 live on ClinicalTrials.gov.